New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
16:42 EDTVRTXVertex receives European approval for KALYDECO in eight gating mutations
Vertex Pharmaceuticals announced that the European Commission has approved KALYDECO for people with cystic fibrosis ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator gene. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today’s approval are G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
September 17, 2014
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information
September 10, 2014
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
September 9, 2014
11:47 EDTVRTXStocks with call strike movement; FSLR VRTX
First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.
September 8, 2014
11:05 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
September 5, 2014
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use